SS-31’s changing global status: what Philippine readers should verify locally

TL;DR

• SS-31 is also known as elamipretide, but a shared molecule name does not make every similarly named item the same regulated product.¹
• A small controlled Barth syndrome trial missed both primary endpoints, while later observations came from an open-label extension without a concurrent placebo group.²
• The United States granted one named elamipretide product a narrow accelerated approval in 2025, with clinical benefit still subject to a required confirmatory trial.³
• Filipino readers should verify the exact product and establishment through the Philippine FDA system because a U.S. decision does not settle Philippine status.⁴

In the Philippines, the phrase “SS-31 is approved” can sound clear at first and incomplete.⁵ A United States decision changed the global conversation in 2025, but it covered a named product and a narrow setting.⁵ The record also includes a controlled result, later open-label observations, and a confirmation step.² Reading those layers one by one helps prevent foreign news from becoming a false local claim.⁴

Start with the names, then separate the products

SS-31 is a research name for elamipretide, which has also appeared as MTP-131 and Bendavia.¹ It is a short peptide designed to reach the inner membrane of mitochondria, the small parts that help cells manage energy.¹ There it interacts with cardiolipin, a membrane fat that helps give mitochondria their shape.¹

That mechanism explains why researchers have tested elamipretide across several mitochondrial conditions.⁶ It does not mean all those conditions share one result.⁶ It also does not make every online listing labeled “SS-31” identical to the United States product Forzinity.⁵ A molecule name, a brand, study material, and a catalog entry are different things.⁴

SS-31 is named here only as the neutral catalog reference below.¹

The controlled Barth trial came first

TAZPOWER studied people with genetically confirmed Barth syndrome, a rare inherited mitochondrial disorder.² Twelve people entered its randomized crossover phase.² Each person received elamipretide and placebo in separate periods, so researchers could compare that person under both conditions.²

The two primary measures were distance covered in a six-minute walk and a fatigue score made for Barth syndrome.² Elamipretide was not superior to placebo on either primary endpoint during the controlled phase.² That negative result matters because primary endpoints are the questions a trial is designed to answer first.²

It is equally important not to stretch the finding.² The trial was very small and covered one disease, one period, and two measures.² It did not settle every possible measure or every mitochondrial condition.⁶

The extension changed the evidence picture

After the controlled phase, ten participants entered an open-label extension, meaning everyone knew they were receiving elamipretide.⁷ Eight participants remained through week 168.⁷ The U.S. label reports that knee extensor strength increased during this extension, although such increases were not observed during the randomized phase.⁷

This is useful evidence, but its design changes the question.⁷ Without a placebo group at the same time, the change is harder to separate from time, who stayed, test practice, or other effects.⁷ The extension should not be described as a repeat of a positive randomized result.⁷

For a Filipino reader scanning headlines, “later improvement” needs that full sentence.⁷ The later observation and the earlier controlled result belong together, not in rival social-media posts.²

Broader mitochondrial research was not one result

Elamipretide was also tested in MMPOWER-3, a separate phase 3 trial of 218 adults with primary mitochondrial myopathy.⁶ That name covers gene disorders that can impair how muscles make and use cell energy.⁶ The people and disease mix differed from those in the Barth syndrome program.⁶

At 24 weeks, the trial found no improvement over placebo in its main six-minute walk or fatigue outcomes.⁶ This finding adds human context, yet it cannot cancel or confirm the narrower Barth syndrome question.⁶ The diseases, entry rules, measures, and follow-up were not the same.⁶

The practical reading rule is to keep every result attached to its study label.⁶ “Mitochondrial research” is a field, not one interchangeable pool of participants or outcomes.⁶

What the 2025 U.S. decision actually changed

On September 19, 2025, the United States FDA granted Forzinity, whose active molecule is elamipretide, accelerated approval.⁵ The scope was narrow: muscle strength in adults and children with Barth syndrome weighing at least 30 kilograms.⁵ That wording does not create a broad approval for wellness, aging, sport, or every mitochondrial diagnosis.⁵

Accelerated approval is a specific path, not another term for final proof.³ Here, the FDA relied on knee extensor strength as an intermediate endpoint considered reasonably likely to predict patient benefit.³ This type of endpoint is expected to relate to how a person feels or functions, but it is not direct proof of that broader benefit.³

The decision changed United States status while leaving a research duty in place.⁸

Confirmation is now part of the status

The FDA requires a randomized, double-blind, placebo-controlled trial to verify and describe the clinical benefit predicted by the strength measure.⁸ Its public accelerated-approval table lists March 31, 2030, as the final report due date.⁸ A deadline is a regulatory milestone, not a forecast of the result.⁸

ClinicalTrials.gov lists the study, called 4TAZPower, as recruiting.⁹ The registry describes a masked, randomized, placebo-controlled design, an estimated 48 people, and estimated completion in 2029.⁹ Those details show the study plan and its current status.⁹ They do not prove a positive outcome before the results are collected and reviewed.⁹

This is why “approved” and “still being confirmed” can both be accurate in an accelerated-approval story.³ Each phrase answers a different question.⁸

A Philippine check needs Philippine records

The Philippine FDA Verification Portal is the local public source for products with a Certificate of Product Registration or Notification and firms with a License to Operate.¹⁰ These are two checks: one covers the exact product, while the other covers the business linked to it.¹⁰

For registered drugs, the Philippine FDA says approved package inserts and patient information leaflets are posted through the portal and updated monthly.¹¹ A careful check should match the generic name, brand, registration number, company, issue date, expiry date, and official product information where shown.¹¹ A cropped screenshot or foreign label cannot replace that current local record.¹¹

The Philippine FDA also provides a route for additions or corrections to the registered-drug list.¹² If a search is unclear, check spelling and identifiers, then seek direct clarification instead of declaring that a record does not exist.¹²

For readers comparing nearby catalog topics, the MOTS-c card below opens its live catalog details. It is a separate reference, not research evidence or a recommendation.

Bottom line

SS-31’s status changed because the United States FDA gave the named elamipretide product Forzinity a narrow accelerated approval in 2025.⁵ The decision did not erase the controlled Barth trial’s missed main endpoints or the limits of its small open-label extension.² It also did not end the research process: the FDA requires a confirmatory trial, and the official registry lists that study as recruiting.⁹ For Filipino readers, the sound response is care, not hype or scorn.⁴ Keep the molecule, brand, use, country, trial design, and current record separate.⁴ Then verify the exact local product and firm through Philippine FDA sources.¹⁰

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

Are SS-31 and elamipretide the same name?

SS-31 is a research name used for elamipretide, while MTP-131 and Bendavia have also appeared in its development history.¹ Forzinity is the name of the specific product approved in the United States.⁵ Shared molecule wording does not show that a separate catalog or online item is that regulated product.⁴

What does accelerated approval mean here?

The United States FDA based this accelerated approval on knee extensor strength, an intermediate endpoint considered reasonably likely to predict patient benefit.³ It was not direct proof of the broader benefit.³ Continued approval may depend on the required trial meant to verify and describe that benefit.⁸

Did the randomized Barth syndrome trial meet its main goals?

No. In the controlled crossover phase, elamipretide was not superior to placebo on the six-minute walk or Barth syndrome fatigue primary endpoints.² Later knee-strength observations came from an open-label extension without a concurrent placebo group, so they carry a different design and interpretation.⁷

Does the U.S. decision establish Philippine approval?

No. The United States decision applies to a named product, use, and country.⁵ Philippine status requires a separate check through the Philippine FDA system, which posts product registration data and firm licenses.¹⁰ The exact local entry and official documents are the records for that question.⁴

What should I compare in the Philippine FDA portal?

Match the exact generic name, brand, registration number, company details, issuance date, expiry date, and official product information where present.¹¹ Also check the connected establishment’s License to Operate, because product registration and establishment licensing answer different questions.¹⁰ Recheck spelling if the first search is unclear.¹²

Does a recruiting confirmatory trial prove the product works?

No. ClinicalTrials.gov currently describes 4TAZPower as a recruiting, randomized, masked, placebo-controlled study with estimated enrollment and completion dates.⁹ A registry entry tells readers about the study plan and progress.⁹ It does not supply a positive result before the trial is completed and analyzed.⁹

Sources

Footnotes

1. FORZINITY (elamipretide) U.S. Prescribing Information; A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Official U.S. labeling and a published Barth syndrome trial describe the molecule and proposed mitochondrial interaction. A name or mechanism does not establish a clinical outcome, product identity, or regulatory status in every country. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

2. FORZINITY (elamipretide) U.S. Prescribing Information; A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Small randomized, double-blind, placebo-controlled crossover study in Barth syndrome. The sample was very small, and the result belongs to the specified endpoints, participants, and controlled period. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

3. FORZINITY (elamipretide) U.S. Prescribing Information; FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. Official explanation of the accelerated approval basis. Continued approval may depend on a confirmatory trial that verifies and describes clinical benefit. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

4. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome; FDA Circular No. 2023-008: Guidelines on Publishing Drug Package Inserts and Patient Information Leaflets in the FDA Verification Portal; Posting of Registered Drug Products at the FDA Verification Portal. Jurisdiction-specific comparison of the U.S. approval announcement and Philippine FDA verification system. Do not transfer a brand, indication, authorization, or establishment status from one country to another. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

5. FORZINITY (elamipretide) U.S. Prescribing Information; FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. Official U.S. approval announcement and prescribing information. The decision applies to the named U.S. product, jurisdiction, indication, and patient scope; it is not a broad approval of every item called SS-31. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

6. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Phase 3 randomized, double-blind, placebo-controlled trial in a genetically diverse primary mitochondrial myopathy population. This was a different disease population from Barth syndrome and does not decide the narrower Barth syndrome question. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

7. FORZINITY (elamipretide) U.S. Prescribing Information. Official U.S. label summary of the randomized study and long-term open-label extension. An open-label extension lacks a concurrent placebo group and is more vulnerable to time effects, selection, and measurement bias. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

8. Ongoing Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals. Current FDA table of ongoing accelerated approvals and postmarketing requirements. A required trial and due date do not predict the future result or a later regulatory decision. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

9. Clinical Trial in Patients With Barth Syndrome — 4TAZPower. Current official study registry entry for NCT07531251. A registry entry describes a plan and status; it does not establish a positive outcome. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

10. FDA Circular No. 2023-008: Guidelines on Publishing Drug Package Inserts and Patient Information Leaflets in the FDA Verification Portal. Philippine FDA circular defining the portal and its public purpose. A product record and an establishment record answer different verification questions and should both be matched exactly. ↩ ↩² ↩³ ↩⁴ ↩⁵

11. FDA Circular No. 2023-008: Guidelines on Publishing Drug Package Inserts and Patient Information Leaflets in the FDA Verification Portal. Philippine FDA rules for public posting of approved drug information. Readers should use the latest official entry and document rather than a reposted label or screenshot. ↩ ↩² ↩³ ↩⁴

12. Posting of Registered Drug Products at the FDA Verification Portal. Philippine FDA announcement on public posting and registry maintenance. An unsuccessful name search should lead to spelling checks and direct clarification, not a definitive claim that a record or authorization does not exist. ↩ ↩² ↩³